Shopping Cart 0
Cart Subtotal
USD 0

Spectrum Pharmaceuticals Inc (SPPI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Spectrum Pharmaceuticals Inc (Spectrum) is a biotechnology company that develops and commercializes a pipeline of late-stage clinical and commercial products with focus on hematology and oncology. The company's marketed drugs include Fusilev (levoleucovorin); Folotyn (pralatrexate injection); Zevalin (ibritumomab tiuxetan); Marqibo (vincristine sulfate liposome injection), Beleodaq (belinostat) and Evomela (Captisol-Enabled Melphalan). It also has drugs in mid-to-late stage development, namely, Rolontis (eflapegrastim) for chemotherapy-induced neutropenia; Qapzola (apaziquone) for Intravesical Instillation; and Poziotinib for the treatment of various types of cancers. The company markets its products through direct sales force in the US and through distributors in Europe. Spectrum is headquartered in Henderson, Nevada, the US.

Spectrum Pharmaceuticals Inc (SPPI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Spectrum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

myTomorrows Enters into Agreement with Spectrum Pharma 14

Spectrum Pharma Enters into Agreement with Servier Canada 15

Eagle Pharma Enters into Agreement with Spectrum Pharma 16

Licensing Agreements 17

Spectrum Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer 17

Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 18

Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 20

Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 21

Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 23

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 24

Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 26

Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 27

Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 28

Spectrum Pharma Amends Licensing Agreement With TopoTarget For Belinostat 29

Equity Offering 30

Spectrum Pharma Raises USD90.2 Million in Private Placement of Shares 30

Spectrum Pharma Raises USD3 Million in Private Placement of Shares 32

Spectrum Pharma to Raise USD100 Million in Public Offeirng of Shares 33

Talon Therapeutics Completes Private Placement Of Preferred Stock For USD 11 Million 34

Debt Offering 36

Spectrum Pharma Completes Private Placement Of Notes Due 2018 For USD 100 Million 36

Acquisition 38

Spectrum Pharmaceuticals May Sell Itself 38

Spectrum Pharma Acquires Majority Stake In Talon Therapeutics 39

Spectrum Pharma Completes Acquisition Of Allos Therapeutics For USD206 Million 41

Spectrum Pharmaceuticals Inc-Key Competitors 43

Spectrum Pharmaceuticals Inc-Key Employees 44

Spectrum Pharmaceuticals Inc-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Joint Venture 46

Recent Developments 47

Financial Announcements 47

Aug 09, 2018: Spectrum Pharmaceuticals reports second quarter 2018 financial results and pipeline update 47

May 03, 2018: Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update 49

Mar 06, 2018: Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update 51

Nov 02, 2017: Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update 53

Aug 03, 2017: Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update 55

May 02, 2017: Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update 56

Mar 08, 2017: Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update 57

Corporate Communications 59

Oct 18, 2018: Spectrum Pharmaceuticals names Dr. Francois Lebel as chief medical officer 59

Feb 27, 2018: Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its Board of Directors 60

Dec 17, 2017: Spectrum Pharmaceuticals Announces Leadership Changes 61

Product News 62

12/04/2017: Spectrum Pharmaceuticals To Present Abstracts On MARQIBO At The 59th Annual Meeting Of The ASH in Atlanta, Georgia, December 9-12, 2017 62

06/02/2017: Spectrum Pharmaceuticals Announces Presentation on MARQIBO at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017 63

06/02/2017: Spectrum Pharmaceuticals Highlights Clinical Data on FOLOTYN at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017 64

Product Approvals 65

Sep 07, 2017: CASI Provides Update on MARQIBO 65

Clinical Trials 66

Jun 19, 2017: Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting 66

Other Significant Developments 67

Apr 30, 2018: Spectrum Pharmaceuticals announces corporate governance enhancements and board changes 67

Apr 27, 2018: Company Profile for Spectrum Pharmaceuticals 68

Mar 07, 2018: Spectrum Pharmaceuticals to present corporate update at the Cowen and Company 38th annual health care conference on March 13th 69

Appendix 70

Methodology 70

About GlobalData 70

Contact Us 70

Disclaimer 70


List Of Figure

List of Figures

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Spectrum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Spectrum Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Spectrum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

myTomorrows Enters into Agreement with Spectrum Pharma 14

Spectrum Pharma Enters into Agreement with Servier Canada 15

Eagle Pharma Enters into Agreement with Spectrum Pharma 16

Spectrum Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer 17

Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 18

Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 20

Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 21

Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 23

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 24

Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 26

Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 27

Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 28

Spectrum Pharma Amends Licensing Agreement With TopoTarget For Belinostat 29

Spectrum Pharma Raises USD90.2 Million in Private Placement of Shares 30

Spectrum Pharma Raises USD3 Million in Private Placement of Shares 32

Spectrum Pharma to Raise USD100 Million in Public Offeirng of Shares 33

Talon Therapeutics Completes Private Placement Of Preferred Stock For USD 11 Million 34

Spectrum Pharma Completes Private Placement Of Notes Due 2018 For USD 100 Million 36

Spectrum Pharmaceuticals May Sell Itself 38

Spectrum Pharma Acquires Majority Stake In Talon Therapeutics 39

Spectrum Pharma Completes Acquisition Of Allos Therapeutics For USD206 Million 41

Spectrum Pharmaceuticals Inc, Key Competitors 43

Spectrum Pharmaceuticals Inc, Key Employees 44

Spectrum Pharmaceuticals Inc, Other Locations 45

Spectrum Pharmaceuticals Inc, Subsidiaries 45

Spectrum Pharmaceuticals Inc, Joint Venture 46

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Spectrum Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Spectrum Pharmaceuticals Inc (Spectrum) is a biotechnology company that develops and commercializes a pipeline of late-stage clinical and commercial products with focus on hematology and oncology. The company's marketed drugs include Fusilev (levoleucovorin); Folotyn (pralatrexate injection); Zevalin (ibritumomab tiuxetan); Marqibo (vincristine sulfate liposome injection), Beleodaq (belinostat) and Evomela (Captisol-Enabled Melphalan). It also has drugs in mid-to-late stage development, namely, Rolontis (eflapegrastim) for chemotherapy-induced neutropenia; Qapzola (apaziquone) for Intravesical Instillation; and Poziotinib for the treatment of various types of cancers. The company markets its products through direct sales force in the US and through distributors in Europe. Spectrum is headquartered in Henderson, Nevada, the US.

Spectrum Pharmaceuticals Inc (SPPI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Spectrum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

myTomorrows Enters into Agreement with Spectrum Pharma 14

Spectrum Pharma Enters into Agreement with Servier Canada 15

Eagle Pharma Enters into Agreement with Spectrum Pharma 16

Licensing Agreements 17

Spectrum Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer 17

Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 18

Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 20

Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 21

Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 23

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 24

Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 26

Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 27

Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 28

Spectrum Pharma Amends Licensing Agreement With TopoTarget For Belinostat 29

Equity Offering 30

Spectrum Pharma Raises USD90.2 Million in Private Placement of Shares 30

Spectrum Pharma Raises USD3 Million in Private Placement of Shares 32

Spectrum Pharma to Raise USD100 Million in Public Offeirng of Shares 33

Talon Therapeutics Completes Private Placement Of Preferred Stock For USD 11 Million 34

Debt Offering 36

Spectrum Pharma Completes Private Placement Of Notes Due 2018 For USD 100 Million 36

Acquisition 38

Spectrum Pharmaceuticals May Sell Itself 38

Spectrum Pharma Acquires Majority Stake In Talon Therapeutics 39

Spectrum Pharma Completes Acquisition Of Allos Therapeutics For USD206 Million 41

Spectrum Pharmaceuticals Inc-Key Competitors 43

Spectrum Pharmaceuticals Inc-Key Employees 44

Spectrum Pharmaceuticals Inc-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Joint Venture 46

Recent Developments 47

Financial Announcements 47

Aug 09, 2018: Spectrum Pharmaceuticals reports second quarter 2018 financial results and pipeline update 47

May 03, 2018: Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update 49

Mar 06, 2018: Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update 51

Nov 02, 2017: Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update 53

Aug 03, 2017: Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update 55

May 02, 2017: Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update 56

Mar 08, 2017: Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update 57

Corporate Communications 59

Oct 18, 2018: Spectrum Pharmaceuticals names Dr. Francois Lebel as chief medical officer 59

Feb 27, 2018: Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its Board of Directors 60

Dec 17, 2017: Spectrum Pharmaceuticals Announces Leadership Changes 61

Product News 62

12/04/2017: Spectrum Pharmaceuticals To Present Abstracts On MARQIBO At The 59th Annual Meeting Of The ASH in Atlanta, Georgia, December 9-12, 2017 62

06/02/2017: Spectrum Pharmaceuticals Announces Presentation on MARQIBO at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017 63

06/02/2017: Spectrum Pharmaceuticals Highlights Clinical Data on FOLOTYN at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017 64

Product Approvals 65

Sep 07, 2017: CASI Provides Update on MARQIBO 65

Clinical Trials 66

Jun 19, 2017: Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting 66

Other Significant Developments 67

Apr 30, 2018: Spectrum Pharmaceuticals announces corporate governance enhancements and board changes 67

Apr 27, 2018: Company Profile for Spectrum Pharmaceuticals 68

Mar 07, 2018: Spectrum Pharmaceuticals to present corporate update at the Cowen and Company 38th annual health care conference on March 13th 69

Appendix 70

Methodology 70

About GlobalData 70

Contact Us 70

Disclaimer 70


List Of Figure

List of Figures

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Spectrum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Spectrum Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Spectrum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

myTomorrows Enters into Agreement with Spectrum Pharma 14

Spectrum Pharma Enters into Agreement with Servier Canada 15

Eagle Pharma Enters into Agreement with Spectrum Pharma 16

Spectrum Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer 17

Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 18

Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 20

Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 21

Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 23

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 24

Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 26

Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 27

Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 28

Spectrum Pharma Amends Licensing Agreement With TopoTarget For Belinostat 29

Spectrum Pharma Raises USD90.2 Million in Private Placement of Shares 30

Spectrum Pharma Raises USD3 Million in Private Placement of Shares 32

Spectrum Pharma to Raise USD100 Million in Public Offeirng of Shares 33

Talon Therapeutics Completes Private Placement Of Preferred Stock For USD 11 Million 34

Spectrum Pharma Completes Private Placement Of Notes Due 2018 For USD 100 Million 36

Spectrum Pharmaceuticals May Sell Itself 38

Spectrum Pharma Acquires Majority Stake In Talon Therapeutics 39

Spectrum Pharma Completes Acquisition Of Allos Therapeutics For USD206 Million 41

Spectrum Pharmaceuticals Inc, Key Competitors 43

Spectrum Pharmaceuticals Inc, Key Employees 44

Spectrum Pharmaceuticals Inc, Other Locations 45

Spectrum Pharmaceuticals Inc, Subsidiaries 45

Spectrum Pharmaceuticals Inc, Joint Venture 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Spectrum Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.